Want to see VCYT full AI Analyst Report?
VCYT Stock Chart & Stats
$56.61
-$1.27(-2.19%)
At close: 4:00 PM EDT
$56.61
-$1.27(-2.19%)
Day’s Range― - ―
52-Week Range$28.25 - $60.91
Previous Close$55.6
Volume589.88K
Average Volume (3M)1.26M
Market Cap
$3.38B
Enterprise Value$4.37K
Total Cash (Recent Filing)$485.23M
Total Debt (Recent Filing)$40.11M
Price to Earnings (P/E)28.4
Beta1.14
Next Earnings
Nov 10, 2026EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.44
Shares Outstanding80,390,730
10 Day Avg. Volume1,010,796
30 Day Avg. Volume1,260,045
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)2.53
Price to Sales (P/S)6.40
P/FCF Ratio26.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$57.75Price Target Upside2.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)1.9
Revenue Forecast (FY)$593.64M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Margin ExpansionDouble-digit testing growth combined with higher gross and EBITDA margins indicates increasing assay adoption and operating leverage. Sustained volume, pricing and workflow improvements could support durable profitability as Veracyte scales its laboratory platform.
Strong Cash Generation And Low LeverageRobust cash conversion and minimal debt give Veracyte flexibility to fund R&D, commercialization and launches without relying heavily on external capital. This strengthens resilience and supports continued investment in its diagnostic portfolio.
Clinical Evidence And Product PipelineA growing clinical evidence base, research databases and multiple genomic products can deepen physician adoption and broaden Veracyte’s addressable markets. Successful launches would diversify growth beyond current assays and reinforce its evidence-led competitive position.
Bears Say
Reimbursement And Guideline Timing RiskDiagnostic utilization depends on payer coverage, coding and clinical guidelines. Delays in publication, guideline updates or reimbursement decisions could postpone broader adoption, limit realized revenue per test and make the growth trajectory less predictable.
Clinical Readout And Adoption RiskKey trial outcomes influence product labels, guideline support and physician confidence. An unfavorable or delayed readout could reduce the commercial potential of new offerings and slow expansion of the company’s diagnostic testing franchise.
Growth Durability And Operational VariabilityAlthough current performance is strong, slower growth and prior periods of losses show that results have not yet been fully proven across business cycles. Seasonal sample-quality effects may also pressure test volumes, collections and margins.
Veracyte News
VCYT FAQ
What was Veracyte Inc’s price range in the past 12 months?
Veracyte Inc lowest stock price was $28.25 and its highest was $60.91 in the past 12 months.
What is Veracyte Inc’s market cap?
Veracyte Inc’s market cap is $3.38B.
When is Veracyte Inc’s upcoming earnings report date?
Veracyte Inc’s upcoming earnings report date is Nov 10, 2026 which is in 82 days.
How were Veracyte Inc’s earnings last quarter?
Veracyte Inc released its earnings results on Jul 30, 2026. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.13.
Is Veracyte Inc overvalued?
According to Wall Street analysts Veracyte Inc’s price is currently Undervalued.
Does Veracyte Inc pay dividends?
Veracyte Inc does not currently pay dividends.
What is Veracyte Inc’s EPS estimate?
Veracyte Inc’s EPS estimate is 0.41.
How many shares outstanding does Veracyte Inc have?
Veracyte Inc has 80,390,730 shares outstanding.
What happened to Veracyte Inc’s price movement after its last earnings report?
Veracyte Inc reported an EPS of $0.54 in its last earnings report, beating expectations of $0.41. Following the earnings report the stock price went down -22.516%.
Which hedge fund is a major shareholder of Veracyte Inc?
Currently, no hedge funds are holding shares in VCYT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veracyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$57.75 (2.01% Upside)
$57.75 (2.01% Upside)
Blogger Sentiment
Bearish
VCYT Sentiment 67%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 10.4%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
139.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.58%
Trailing 12-Months
Company Description
Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
VCYT Company Deck
VCYT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial picture: double-digit revenue and volume growth, margin expansion, robust adjusted EBITDA (30.8%), strong cash generation, and multiple near-term product catalysts (Prosigna LDT and TruMRD). The company emphasized a deep clinical evidence base, sustained Decipher momentum, operational wins on Afirma (V2 workflow), and continued investment in R&D and commercialization. Key risks discussed were binary clinical readouts (OPTIMA/ENZIMET), exclusion of new-product revenue from guidance, PPC variability, seasonal sample quality impacts, and the need for guideline/reimbursement progress—factors that inject execution and timing uncertainty but do not currently outweigh the suite of positive financial and commercial indicators.View all VCYT earnings summariesVCYT Stock 12 Month Forecast
Average Price Target
$57.75
▲(2.01% Upside)
Technical Analysis
Travere Therapeutics
―
Celcuity
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Ownership Overview
1.77% Insiders
34.08% Mutual Funds
22.03% Other Institutional Investors
6.67% Public Companies and
Individual Investors